Innovative Treatments for Central Nervous System Disorders November 2023 Allosteric modulators for human health Disclaimer These materials do not constitute or form part, or all, of any offer or invitation to sell or issue, neither in the United States of America nor elsewhere, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall part, or all, of these materials or their distribution form the basis of, or be relied on in connection with, any contract or investment decisio ...

Addex Therapeutics Ltd. (NASDAQ:ADXN) Q3 2023 Earnings Conference Call November 29, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speake ...

Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and nine-month periods ended September 30, 2023 and 20223 Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the nine- ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2023 Results Conference Call August 10, 2023 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Robert Lutjens - Head of Discovery-Biology Mikhail Kalinichev - Head of Transition Science Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics Half Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a liste ...

Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of June 30, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month and six-month periods ended 3 June 30, 2023 and 2022 Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the six-month perio ...

Addex Therapeutics Ltd. (NASDAQ:ADXN) Q1 2023 Earnings Conference Call May 11, 2023 10:00 AM ET Company Participants Timothy Dyer – Chief Executive Officer Robert Lütjens – Head of Discovery-Biology Conference Call Participants Boobalan Pachaiyappan – H.C. Wainwright Leonildo Delgado – Baader Helvea Timothy Dyer Hello, everyone. I would like to thank you all for attending our First Quarter 2023 Financial Results Conference Call. I'm here with Robert Lütjens, our Head of Discovery Biology. I draw your attent ...

Financial Performance - Revenue from contracts with customers increased to CHF 500,892 for the three months ended March 31, 2023, compared to CHF 237,237 for the same period in 2022, marking a growth of approximately 111%[7] - Total revenue for Q1 2023 was CHF 502,047, up from CHF 243,948 in Q1 2022, marking a 106% increase[39] - Net loss for the period narrowed to CHF 2,407,169 in Q1 2023 from CHF 5,823,735 in Q1 2022, indicating an improvement of approximately 59%[7] - The loss attributable to equity holders for Q1 2023 was CHF 2,407,169, an improvement from 5,823,735 in Q1 2022[83] - Basic and diluted loss per share improved to CHF (0.04) in Q1 2023 from CHF (0.15) in Q1 2022[7] Operating Costs - Total operating costs decreased from CHF 6,006,533 in Q1 2022 to CHF 2,901,552 in Q1 2023, a reduction of approximately 52%[7] - Total operating costs for Q1 2023 decreased to CHF 2,901,552, down CHF 3.1 million from CHF 6,006,533 in Q1 2022, primarily due to reduced external research and development expenses[76][77] - General and administration expenses decreased from CHF 2,241,086 in Q1 2022 to CHF 1,197,577 in Q1 2023, a decline of approximately 47%[7] - Research and development expenses were CHF 1,703,975 in Q1 2023, down from CHF 3,765,447 in Q1 2022, a reduction of approximately 55%[7] - Total staff costs for Q1 2023 were CHF 1,343,428, a decrease of CHF 0.8 million compared to CHF 2,192,973 in Q1 2022, mainly due to lower share-based service costs[80] Cash and Assets - Total assets decreased from CHF 8,282,050 as of December 31, 2022, to CHF 7,294,522 as of March 31, 2023, representing a decline of approximately 12%[4] - Cash and cash equivalents decreased from CHF 6,957,086 as of December 31, 2022, to CHF 5,594,872 as of March 31, 2023, a decline of approximately 20%[4] - Cash and cash equivalents at the end of the period were CHF 5,594,872, down from CHF 14,887,838 at the end of the same period in 2022, reflecting a decrease of 62.4%[18] - Other current assets increased to CHF 1,319,871 as of March 31, 2023, compared to CHF 871,875 as of December 31, 2022, an increase of 51%[45] - Total equity decreased from CHF 4,912,911 as of December 31, 2022, to CHF 4,071,228 as of March 31, 2023, a decrease of approximately 17%[4] Cash Flow and Financing - Net cash used in operating activities decreased to CHF 2,359,437 from CHF 4,844,624, indicating a 51.3% reduction in cash outflow[18] - The Group's cash flows from financing activities resulted in a net cash inflow of CHF 1,028,343, contrasting with a net cash outflow of CHF 744,352 in the prior year[18] - The Group's existing cash and cash equivalents are expected to be insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern[27] - The Group is exploring options to obtain additional funding through collaborations and public or private financings to support future operations[27] Shareholder Information - The total number of shares outstanding as of March 31, 2023, was 80,871,291, excluding 34,477,020 treasury shares[56] - The Group sold 3,742,506 treasury shares at an average price of CHF 0.31 per share, generating gross proceeds of CHF 1,176,781 during Q1 2023[57] - Total share-based compensation expense for Q1 2023 was CHF 431,196, a decrease of CHF 1.0 million from CHF 1,440,052 in Q1 2022[13] - The Group's share-based compensation expense was CHF 431,196 for the period, down from CHF 1,440,052 in the same period last year, indicating a 70% decrease[18] Revenue Recognition - The Group's revenue primarily comes from fees related to licenses, milestones, and research services, with significant judgment required in revenue recognition[30] - Collaborative research funding revenue increased to CHF 500,892 in Q1 2023 from CHF 237,237 in Q1 2022, representing a growth of 111%[37] - Other service income decreased to CHF 1,155 in Q1 2023 from CHF 6,711 in Q1 2022, a decline of 83%[37]

Financial Data and Key Metrics Changes - The company recognized $1.4 million of income in 2022, a decrease from $3.2 million in 2021, primarily due to reduced research funding from collaboration with Indivior [26] - R&D expenses increased to $14.7 million in 2022 from $12.8 million in 2021, attributed to increased outsourced clinical activities and share-based compensation [26] - G&A expenses rose to $7.3 million in 2022 from $5.8 million in 2021, mainly due to increased share-based compensation costs [27] - The company ended 2022 with CHF 7 million in cash, down from $20.5 million at the start of the year, after consuming $17.6 million in operations [28] Business Line Data and Key Metrics Changes - The collaboration with Indivior was extended, with an additional research funding of $1.8 million expected [5] - The mGlu2 NAM program faced challenges during the clinical candidate selection phase, leading to a return to lead optimization [5] - The M4 PAM program for schizophrenia is progressing rapidly through lead optimization, especially following positive Phase III data from a competitor [5][6] Market Data and Key Metrics Changes - The market opportunity for ADX71149 in epilepsy is significant, with over 2 million patients on Keppra, which generates close to $1 billion in annual sales [7][8] - The company has retained significant economic rights in its deal with Janssen, including prelaunch milestones of EUR 109 million and low double-digit royalties on net sales [8] Company Strategy and Development Direction - The company is focusing on advancing its preclinical pipeline, with multiple candidates moving towards IND-enabling studies [25] - Future development plans for dipraglurant include exploring indications in post-stroke recovery and pain management [29] - The company aims to secure partnerships to strengthen its balance sheet and advance its portfolio [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged disappointing stock performance and market capitalization but expressed optimism about ongoing business discussions and potential partnerships [30] - The company is evaluating the future development of dipraglurant and believes in its value for treating PD-LID and other indications [29] Other Important Information - The company implemented cost-saving measures that significantly reduced monthly cash burn, providing a runway through the end of Q3 2023 [6] - The independent interim review committee established by Janssen will provide recommendations on the ADX71149 study in early Q2 2023 [11][28] Q&A Session Summary Question: What might Janssen consider an unexpectedly positive outcome from the epilepsy proof-of-concept study? - Management explained that Janssen is looking for a go/no-go decision based on how many patients reached their baseline seizure count in Part 1 of the study [32][33] Question: How does the M4 allosteric modulator compare to xanomeline plus trospium? - Management highlighted that their approach uses a selective positive allosteric modulator, which may avoid tolerance issues seen with agonists [35][36] Question: Why has the compensation for the Board and executives increased significantly? - The increase is linked to a reorganization of the share-based compensation program, driven by IFRS 2 calculations [40][41] Question: Why are IND-enabling studies for GABAB not happening earlier? - Management noted that Indivior is conducting thorough profiling of compounds, which has delayed the selection process [44][45] Question: Are patients being recruited for the second part of the ADX71149 study? - Management confirmed that recruitment is ongoing and that patients from Part 1 who did not meet their baseline seizure count have rolled over into Part 2 [47][49]

EXHIBIT 99.1 Addex Reports Full Year 2022 Financial Results and Provides Corporate Update CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022 ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical- stage pharmaceutical company pioneering allosteric modulation-based ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...